
ICON appoints vice president from Allergan
pharmafile | September 4, 2014 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | ICON, ira spector
Healthcare outsourced development firm ICON has hired Dr Ira Spector to be the executive vice president of its analytics and consulting unit.
In this role Spector will lead ICON’s consulting and drug development services, and will also be responsible for its business process improvement and analytics capabilities.
Spector takes over 25 years of experience managing drug and medical device development programmes to the firm, and joins ICON from Allergan Pharmaceuticals where he was senior VP of its global development operations.
Prior to Allergan Spector spent 17 years at Wyeth Research, most recently as VP, global development operations and vice-chief of development. He was also VP and a partner at the PA Consulting Group, a business technology consulting firm.
Dr Steve Cutler who is the chief operating officer at ICON, says: “I would like to welcome Dr Spector to the ICON team. His extensive experience in managing some of the world’s largest trials in areas such as oncology, vaccines and CNS, coupled with his expertise in using technology to drive innovation and process improvement, will enable us to provide further strategic input to our customers’ drug and device programmes.”
Related Content

Cloud on the horizon: Cloud computing and the clinical trial
Originally published in the September edition of Pharmafocus, Matt Fellows investigates how cloud computing may …

Icon to acquire Aptiv Solutions
Icon has acquired US clinical trial specialists Aptiv Solutions for $143.5 million as it looks …
Contract research news in brief
Icon offers $52m for CCH’s clinical services division, plus updates from PPD, Aptuit, Argenta, Quintiles …






